Advanced biomaterials for cancer immunotherapy  

作　　者：Fan Yang Kun Shi Yan-peng Jia Ying Hao Jin-rong Peng Zhi-yong Qian 

机构地区：[1]State Key Laboratory of Biotherapy and Cancer Center,West China Hospital,West China Medical School,Sichuan University,Chengdu 610041,China

出　　处：《Acta Pharmacologica Sinica》2020年第7期911-927,共17页中国药理学报（英文版）

基　　金：The National Science Fund for Distinguished Young Scholars(31525009);the National Natural Science Foundation of China(31930067,31800797,and 31771096);the National Key Research and Development Program of China(2017YFC1103502);the China Postdoctoral Science Foundation(2018M631094 and 2019M653410);the 1.3.5 project for disciplines of excellence,West China Hospital,Sichuan University(ZYGD18002).

摘　　要：Immunotherapy,as a powerful strategy for cancer treatment,has achieved tremendous efficacy in clinical trials.Despite these advancements,there is much to do in terms of enhancing therapeutic benefits and decreasing the side effects of cancer immunotherapy.Advanced nanobiomaterials,including liposomes,polymers,and silica,play a vital role in the codelivery of drugs and immunomodulators.These nanobiomaterial-based delivery systems could effectively promote antitumor immune responses and simultaneously reduce toxic adverse effects.Furthermore,nanobiomaterials may also combine with each other or with traditional drugs via different mechanisms,thus giving rise to more accurate and efficient tumor treatment.Here,an overview of the latest advancement in these nanobiomaterials used for cancer immunotherapy is given,describing outstanding systems,including lipid-based nanoparticles,polymer-based scaffolds or micelles,inorganic nanosystems,and others.

关 键 词：cancer IMMUNOTHERAPY NANOBIOMATERIALS nanoparticles liposomes micelles HYDROGEL MICRONEEDLES dendritic cells(DCs) 

分 类 号：R730.51[医药卫生—肿瘤]